期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

培美曲塞联合顺铂治疗晚期非小细胞肺癌的近期疗效及安全性 被引量：38

下载PDF
导出
摘要 目的探讨培美曲塞联合顺铂治疗晚期非小细胞肺癌(NSCLC)的近期疗效及安全性。方法选择NSCLC患者93例,随机分为培美曲赛联合顺铂组(Ⅰ组)45例、多西他赛联合顺铂组(Ⅱ组)48例。Ⅰ组给予注射用培美曲塞二钠+顺铂方案化疗,Ⅱ组给予多西他赛+顺铂方案化疗,21 d为1个疗程,治疗4个疗程。比较两组临床疗效、毒性反应及中位生存期、1年生存率。结果Ⅰ组总有效率为44.4%,Ⅱ组总有效率为43.75%,两组比较P>0.05。随访至2013年1月,Ⅰ组中位生存期为11.6个月、1年生存率为45.2%,Ⅱ组分别为10.4个月、44.1%,两组中位生存期及1年生存率比较P均>0.05。除Ⅰ组Ⅲ～Ⅳ度白细胞减少发生率(6.66%)显著低于Ⅱ组(20.83%)外,其余毒性反应发生率比较差异均无统计学意义(P均>0.05)。结论培美曲塞联合顺铂治疗晚期NSCLC安全、有效,可作为NSCLC临床一线化疗药物。
作者 邴雪 高卫 李明燕
机构地区 潍坊医学院 济南市中心医院 泰山医学院
出处 《山东医药》 CAS 2013年第21期62-64,共3页 Shandong Medical Journal
关键词 非小细胞肺癌 培美曲塞 多西他赛 顺铂
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献12

  • 1Ohe Y. Chemoradiotherapy for lung cancer[ J]. Expert Opin Phar- macother, 2005,6(16) :2793-2804. 被引量：1
  • 2Fossella F, Pereira JR, van Pawel J, et al. Randomized, multina- tional, phase I study of docetaxel plus platinum combinations ver- sus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group [ J]. J Clin Oncol, 2003,21 (16) :3016-3024. 被引量：1
  • 3Scagliotti GV, Parikh P, yon Pawel J, et al. Phase m study com- paring cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive pa tients with advanced-stage non-small-cell lung cancer[J]: J Clin Oncol, 2008,26(21 ) :3543-3551. 被引量：1
  • 4Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized,phase 1/ trial[J]. Clin Cancer Res, 2005,11(2 Pt 1) : 690-696. 被引量：1
  • 5Zinner RG, Fossella FV, Gladish GW, et al. Phase 11 study of pemetrexed in combination with carboplatin in the first-line treal- ment of advanced nonsmall cell lung cancer [ J ]. Cancer, 2005, 104( 11 ) :2449-2456. 被引量：1
  • 6Scagliotti GV, Park K, Patil S, et al. Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in che- monaive patients with advanced non-small cell lung cancer: a risk- benefit analysis of a large phase I study [ J ]. Eur J Cancer, 2009,45 ( 13 ) :2298-2303. 被引量：1
  • 7Greenhalgh J, McLeod C, Bagust A, et al. Pemetrexed for the ma- intenance treatment of locally advanced or metastatic non-small cell lung cancer[ J ]. Health Technol Assess, 2010,14 ( Suppl 2) : 33- 39. 被引量：1
  • 8Hainsworth JD, Cebotam CL, Kanarev V, et al. A phase l/ , open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small-cell lung cancer who have failed one or two prior chemo- therapeutic regimens [ J ]. J Thorac Oncol, 2010,5 ( 10 ) : 1630- 1636. 被引量：1
  • 9Felip E, Rosell R. Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC) [ J]. Ther Clin Risk Manag, 2008_ 4 ( 3 ) .579-5. 被引量：1
  • 10Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cispla- tin for advanced non-squamous non-small-cell lung cancer( PARA- MOUNT): a double-blind, phase 3, randomised controlled trial [J]. Lancet Oncol, 2012,13(3) :247-255. 被引量：1

二级参考文献11

  • 1Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J ned,2002,346(2) :92-98. 被引量：1
  • 2Sandier A,Gray R,Perry MC,et al. Paclitaxelcarboplatinalone or with bevacizumab for non-smallcell lung cancer [J]. N Engl J Med,2006,355(24) :2542-2550. 被引量：1
  • 3Esteban E,Casillas M,Cassinello A. Pemetrexed in first- line treatment of non-small cell lung cancer [J]. Cancer Treatment Reviews, 2009,35 (04) : 364-373. 被引量：1
  • 4Hanna N,Shepherd FA,Fossella FV,et al. Randomized phase m trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy[J]. J Clin Oncol, 2004,22(9) : 1589-1597. 被引量：1
  • 5Scagliotti GV, Parikh P, von Pawel J, et al. Phase m study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with ad- vanced-stage non-small-cell lung cancer[J]. J Clin Oncol, 2008,26(21 ) : 3543-3551. 被引量：1
  • 6Zinner RG,Novello S,Peng G,et al. Comparison of patient outcomes according to histology anaong pemetrexed-treated patients with stage m B/IV non-small-cell lung cancer in two phase trials [J]. Clinical Lung Cancer,2010,11 (2): 126-13l. 被引量：1
  • 7David R,Spigel MD,John D,et al. Phase H study of bi- weekly pemetrexed and gemcitabine in patients with pre- viously untreated advanced non-small cell lung cancer [ J ]. J Thorac Oncol, 2010,5 (6): 841-845. 被引量：1
  • 8Zheng Z,Li X,Schell MJ,et al. Thymidylate synthase in situ protein expression and survival in stage I non-small- cell lung cancer[J]. Cancer,2008,112(12) :2765-2773. 被引量：1
  • 9Grcnberg BH,Bremnes RM,Flctten O,et al. Phase IU study by the Norwegian lung cancer study group:pcme- trexed plus carhoplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non- small-cell lung cancer [J]. J Clin Oncol,2009,27(19): 3217-3224. 被引量：1
  • 10史美祺,沈波,曹国春,曾赟,夏国豪,冯继锋,许林.吉西他滨联合顺铂或卡铂方案治疗晚期非小细胞肺癌的临床对比观察[J].肿瘤基础与临床,2007,20(5):387-389. 被引量：3

共引文献33

同被引文献241

引证文献38

二级引证文献127

山东医药
2013年 第21期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部